7 citations
,
October 2024 in “Frontiers in Immunology” 3 citations
,
October 2024 in “Experimental Dermatology”
April 2024 in “Bioscience trends” Higher levels of certain DNAs in blood may indicate hair follicle damage in alopecia areata patients.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
15 citations
,
October 2022 in “Allergy” Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.
4 citations
,
November 2021 in “Journal of Clinical Medicine” Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.
April 2021 in “Journal of Investigative Dermatology” 23 citations
,
September 2020 in “Journal of Dermatological Science” Targeting Vδ1+T-cells may help treat alopecia areata.
134 citations
,
July 2020 in “Experimental dermatology” Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.
34 citations
,
June 2020 in “British journal of dermatology/British journal of dermatology, Supplement” Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.
58 citations
,
July 2018 in “Journal of Allergy and Clinical Immunology” Alopecia areata severity is linked to increased TH1 and TH2 activity.
64 citations
,
July 2016 in “Journal of Immunology” Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.
16 citations
,
December 2015 in “Journal of Investigative Dermatology” Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.
65 citations
,
December 2015 in “Experimental dermatology” Corticosteroid treatment reduces inflammation and alters hair keratins in alopecia areata.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
May 2015 in “Journal of the Egyptian Women's Dermatologic Society /Journal of the Egyptian Women's Dermatologic Society”
61 citations
,
September 2010 in “Genomics” The study found that immune responses disrupt hair growth cycles, causing hair loss in alopecia areata.
52 citations
,
March 2010 in “British Journal of Dermatology” Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.
58 citations
,
May 2004 in “British Journal of Dermatology” Diphenylcyclopropenone treatment helps hair growth in alopecia areata by promoting blood vessel growth and cell survival.